Google
QNRX — QUOIN PHARMACEUTICALS LTD DRC (Healthcare >> Biotechnology)
QNRX FAQ
What is QNRX's ROE?
QUOIN PHARMACEUTICALS LTD DRC reports a Return on Equity (ROE) of -193.51%.
What is QNRX's dividend yield?
QUOIN PHARMACEUTICALS LTD DRC offers a dividend yield of 0.00%.
What is QNRX's Deepscope Quality Score?
Deepscope rates QNRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy QNRX?
Deepscope's AI Timing Score for QNRX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does QNRX belong to?
QUOIN PHARMACEUTICALS LTD DRC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.20
Price
-0.50
(-10.64%)
Day Change
|
|
|---|
QNRX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.20 |
| PBV / Sector |
1.08 / 4.91
GREAT
|
| Earning Per Share | -7.55 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
0.17 M
GREAT
|
| Average 1W Daily Value |
0.15 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-13 11:13:47 |
| Symbol | QNRX |
| Name | QUOIN PHARMACEUTICALS LTD DRC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.01 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 9.44 / 9,034.83 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349
Phone: 703 980 4182
Website: https://quoinpharma.com
Sector: Healthcare >> Biotechnology
Description: Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
